Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.
People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.
FDA advisors voted against the effectiveness of Biogen’s investigational ALS drug, which could become the first to target a genetic cause of the disease.
Even if the FDA grants full approval of the Alzheimer’s treatment Leqembi, the rollout will take years.
The FDA’s decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer’s.
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}